Tacrolimus Modulates Peripheral Blood NK Cell Subsets and IL-17/IL-10 Ratio in Women With Recurrent Implantation...

Area of Science:

• Reproductive Immunology
• Immunotherapy
• Flow Cytometry & PCR Analysis

Background:

• Recurrent implantation failure (RIF) is associated with immune system dysregulation.
• Tacrolimus shows clinical promise for RIF, but its precise immunological effects are not fully understood.

Purpose of the Study:

• To investigate the impact of tacrolimus on peripheral blood Natural Killer (NK) cell subsets.
• To analyze changes in cytokine profiles, specifically the IL-17/IL-10 ratio, in RIF patients undergoing tacrolimus treatment.

Main Methods:

• Study included 30 women with RIF and 30 fertile controls.
• RIF patients received oral tacrolimus (3 mg/day) prior to embryo transfer.
• NK cell subsets and IL-17/IL-10 expression were measured using flow cytometry and real-time PCR before and after treatment.

Main Results:

• RIF patients exhibited elevated NK cell subsets and an increased IL-17/IL-10 ratio at baseline compared to controls.
• Tacrolimus significantly reduced CD16+, CD56+, and CD16+CD56+ NK cells and decreased IL-17 levels and the IL-17/IL-10 ratio.
• A greater reduction in the IL-17/IL-10 ratio correlated with successful clinical pregnancy, indicating predictive value.

Conclusions:

• Tacrolimus effectively modulates immune responses in RIF by decreasing pro-inflammatory NK cell subsets.
• The drug shifts the IL-17/IL-10 balance towards immune tolerance, supporting its use in RIF immunotherapy.
• Findings suggest tacrolimus is a potential targeted immunotherapy for selected RIF patients.